AC
LJPC

Ascend Capital’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Ascend Capital’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-251,644
Closed -$7.49M – 257
2018
Q1 		$7.49M Buy
251,644
+62,603
+33% +$2.02M 0.3% 105
2017
Q4 		$6.08M Buy
+189,041
New +$6.18M 0.23% 105

Other funds holding LJPC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Ascend Capital's LJPC Position: Q2 2018 in Review

Ascend Capital sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2018, closing a stake of 251,644 shares — an estimated $7.49M sold.

Ascend Capital first reported a position in LJPC in Q4 2017 and held it in 2 quarters. The position peaked at $7.49M in Q1 2018. 95 funds tracked by Wall St. Rank hold LJPC as of Q2 2018.

  • Ascend Capital reported no remaining La Jolla Pharmaceutical Company position as of Q2 2018 after selling out during the quarter.
  • Ascend Capital sold 251,644 La Jolla Pharmaceutical Company shares in Q2 2018, an estimated $7.49M.
  • Ascend Capital first reported a position in La Jolla Pharmaceutical Company in Q4 2017 and held it in 2 quarters.
  • Ascend Capital's La Jolla Pharmaceutical Company position peaked at $7.49M in Q1 2018.
  • 95 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.